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Abstract - The declining value of the dollar and the evolving 
shape of the economy are affecting the value and availability of 
the funds that support the development and commercialization of 
novel cancer technologies.  This conservatism goes against the 
forward advance of translational science, which is beginning to 
show its greatest promise for the pursuit of innovation and the 
dissemination of emerging technologies. Cancer technology 
development is nearing a tipping point in which these countering 
trends may result in a decline of the United States’ ability to 
encourage and foster innovation.  The National Cancer 
Institute’s Innovative Molecular Analysis Technologies (IMAT) 
program is attempting to address this rapidly changing 
environment to ensure that innovation is not stifled.  Discussed is 
an overview of the IMAT program, identified bottlenecks for 
innovation, and a proposed strategy for engaging new partners to 




 The recent decade has witnessed a transformation in 
the practice and study of medicine, catalyzed by an increase in 
the methods and tools available to a clinician for determining 
a patient’s health and treating disease.  Enabled by the 
development and use of various “-omics” based technologies 
(genomics, proteomics, metabolomics, etc.), a more 
personalized medicine promises to provide the clinician with 
the ability to make better informed decisions through 
information generated by the molecular analysis of a patient’s 
specimen.  The resulting readout provides a specific 
description about a patient’s nature of disease and could be 
used to guide the prescription and dosage of therapeutics, 
allowing for immediate optimization of treatment aided by 
real-time measurements of therapeutic efficacy.  This 
information could also be used to design more specific 
pharmaceuticals that minimize adverse side-effects while 
maximizing therapeutic response.  
 
 The integration of innovative technologies into the 
biomedical research and clinical communities is a product of 
the efforts being made in the physical sciences to push the 
limits of detection in their own disciplines, which are then 
translated into novel tools capable of directly observing 
molecular interactions in the human body.  This focus on 
team-based translational medicine has advanced our 
understanding of the basic elemental processes occurring in 
the body as they relate to health and disease, and is part of a 
cycle that continually challenges innovators to incorporate 
newfound knowledge into applications that benefit the health 
of our society.  
 
 In 1998, the National Cancer Institute (NCI) created 
the program for Innovative Molecular Analysis Technologies 
(IMAT, http://innovation.cancer.gov) as an investment in the 
potential of innovation to revolutionize its mission for 
reducing the burden associated with cancer.  The mission of 
the program is to support out-of-the-box approaches towards 
technology development that at the time of inception are 
considered innovative and high risk, but if successful would 
have high-payoffs in advancing research and medicine.  IMAT 
is the primary trans-divisional technology development 
program offered by the NCI, allowing individual innovators to 
access the resources at the NCI and better direct the 
application of their technologies in the areas of basic cancer 
biology, cancer prevention, cancer therapy and detection, or 
cancer control and epidemiological sciences.  
 
IMAT supports the inception and development of 
both innovative and emerging technologies.  The former 
describes those that are built from the ground up, in which 
there exists no current comparison, and the latter are those 
technologies whose development has not reached 
demonstrated feasibility in its intended use, including those 
created by redirecting a currently existing technology for a 
novel application.  As shown in Figure 1, IMAT’s philosophy 
for supporting innovation divides the development of 
technologies into two broadly defined and sequential stages.  
The first step is the demonstration of feasibility through 
strategic pilot studies and IMAT utilizes an NIH R21 funding 
mechanism for this exploratory stage of technical 
development.  Applications submitted to this funding 
opportunity are not required to have preliminary data and 
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Fig. 1. IMAT’s mechanisms to support the pipeline for innovation 
external reviewers base their judgment on the technical 
soundness of the applications as well as potential impact and 
current need.  The second stage of development is supported 
through an NIH R33 funding mechanism for the maturation of 
an innovative technology through scale-up and validation. 
 
Since its establishment, IMAT has supported the 
development of many technologies that are currently 
ubiquitous in clinical research and practice.  One example is 
the Affymetrix chip, a technology that can quantitatively 
measure the expression levels of specific genes.  At its 
inception, the concept of a gene chip was unheard of and 
possibly deemed unrealistic.  Now, this technology is 
routinely used to understand the genetic effects of biochemical 
perturbations, providing the knowledge needed to understand 
the mechanism of disease formation and progression, and thus 
accelerating the discovery of gene-based drug and diagnostic 
targets.  IMAT has also supported the inception and 
development of a life-sciences technology created by a team 
of physicists.  Raindance Technologies’ platform combines 
microfluidics with water-in-oil separation and one application 
has recently entered the commercial market (March 2009).  
The RDT-1000 has pushed the limits of polymerase chain 
reaction’s (PCR) ability to duplicate targeted copies of DNA 
by increasing its speed and precision.  The potential for this 
technology goes beyond improving PCR and Raindance 
Technologies continues to expand this platform to address 
other unmet needs. 
 
 Even with these success stories, the majority of 
IMAT grantees face several bottlenecks that complicate the 
dissemination of their technologies.  The NCI has a 
responsibility to ensure that the investment in the research and 
development of these technologies are not wasted by ensuring 
their dissemination.  To limit the scope of the discussion, this 
manuscript is focused on issues related to pre-tech transfer 
innovation, or the inception stage of technology development.  
The “tech-transfer” milestone, as defined in this manuscript, is 
considered the stage of development in which proof-of-
principle and/or feasibility of a given application has been 
demonstrated and thus should be eligible for intellectual 
property protection.  The bottlenecks at the tech-transfer and 
post-tech transfer stages of technology development are also 
complex, but have already been widely discussed in other 
forums. 
 
Presented in this paper are the findings made from 
assessing the needs of some of the IMAT grantees and a 
proposed solution to those needs.  It is hoped that the 
subsequent roundtable discussion at the Atlanta Conference on 
Science and Innovation Policy will result in insight to help 
ensure that IMAT continues to be a resource for innovation in 







II. BOTTLENECKS FOR DEVELOPING INNOVATIVE 
TECHNOLOGIES 
 
A. Forming the scientific team 
 
 Many scientist-innovators lack the comprehensive 
training and expertise to advance their technologies to the 
commercial market, while at the same time, many business 
development experts lack the rigorous training in the sciences 
to recognize promising avenues for scientific discoveries.  
There are several bottlenecks for translational science that can 
be envisioned by presenting a scenario typical of many 
innovators.  In this scenario, an initial scientific breakthrough 
is made in a life-science laboratory associated with a 
traditional “research one” university.  While many basic 
discoveries are also made in an industrial R&D setting, the 
majority of the discoveries reported in the literature typically 
derive from academic efforts.  The strength of most 
commercial efforts, instead, is more weighted on the 
application of knowledge, rather than its discovery.  In the 
laboratory described in this scenario, scientists used traditional 
molecular biology tools to discover and validate that the 
presence of proteins X and Y are undoubtedly correlated with 
a particular disease.  Although the data supporting the 
discovery and correlation of these biomarkers are solid in this 
scenario, the academic environment is one that traditionally 
encourages the pursuit of additional studies aimed at 
elucidating the exact mechanisms and pathways responsible 
for this correlation, for the goal of many academic scientists is 
to expand the knowledge base through publication of their 
research results.  The pursuit of a patent is sometimes 
considered as a by-product of their efforts, rather than an 
emphasis.  This environment could lead to additional years 
and possibly decades of research before an application is 
synthesized, assuming that no other tangents are made by the 
additional discoveries along the way.  This is the first 
bottleneck; recognition by scientists that they have a discovery 
that could be translated to a broader-use application in the 
laboratory or clinic.  In this instance, the technology could be 
either a diagnostic device or a therapeutic target for the 
disease that proteins X or Y indicate.  This bottleneck is 
further constrained by the dearth of business development 
experts who have the time and/or training to monitor the 
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scientific literature for findings that could lead to an 
application with commercial potential.  
 
 Continuing with this scenario, passing through this 
first bottleneck requires recognition of the potential 
application for the discovery, whereupon the second 
bottleneck is the identification of collaborators and convincing 
them of the potential promise of an innovative technology.  
Most scientists have extensive expertise in their field of study, 
but due to the traditional discipline-based silos of academic 
departments and minimal cross-disciplinary overlap, many 
lack the training and insight to effectively utilize another 
discipline’s approach and tools.  This is where the 
“translation” of science is important and the first step for the 
scientist is to define the type of collaboration that is needed to 
effectively pursue the development of an application. In this 
instance, a collaborator could be an engineer to design and 
fabricate the device, or a chemist to synthesize and 
characterize the drug.  Other collaborators on the scientific 
end of this project include biostatisticians to design the 
experiments and interpret the data, and clinicians to help 
narrow and define its medical impact. 
 
Paralleling this scenario is another one from the 
viewpoint of an academic scientist who has the expertise and 
tools to develop a technology.  These scientists are 
traditionally trained in more physical-science oriented 
disciplines such as chemistry, physics, materials sciences and 
engineering.  In pursuit of their respective department’s 
academic aims, they continue to expand the knowledge base 
and capabilities by synthesizing, characterizing, and 
fabricating technologies that push the limits of size, speed, and 
function.  While the science that they discover might 
revolutionize their own field of study, many of these 
technologies fail to find a direct application and their utility 
remains isolated within their discipline.  This is the bottleneck 
faced by this type of innovator; the inability to find a direct 
application of their technologies, or a lack of direction about 
how to tune their technologies for broader impact.  As with the 
scenario previously presented, this scientist also needs to seek 
collaborators representing potential users of a technology, 
giving the innovator access to the expertise and evaluation 
needed to ensure its application in a real-world setting. 
 
It is then up to either the first scientist to translate the 
importance and impact of their biomarker discovery to the 
other scientists, or for the second scientist to translate the 
capability of their technology, in a grassroots effort to 
convince potential collaborators for a commitment of time and 
resources.  This is no small feat in consideration of other 
complications outside of the scope of this manuscript, which 
include reduced overall funding, the need for additional grant 
applications to compensate for reduced funding in an 
increasingly competitive arena, the need to meet the 
requirements for academic tenure, and the need to continue 
publishing in one’s area of expertise. 
 
The Government, as a principal source of research 
funding, continues to shape science by establishing funding 
mechanisms to catalyze multi-disciplinary research.  In 
addition to IMAT, the NIH has other funding mechanisms 
aimed at supporting team-science approaches toward 
biomedical problems, including initiatives for “Bioengineering 
Research Partnerships” and the “Alliance for Nanotechnology 
in Cancer”, as well as partnerships with other agencies such as 
the National Science Foundation.   
 
Some universities have also taken their own initiative 
to address these bottlenecks by eliminating the silos inherent 
with academic departments.  For example, UCSF’s new 
research campus in Mission Bay, San Francisco, is 
interdisciplinary in design, with the overall appearance of a 
unified unit without any segregation in space or focus on a 
particular discipline.  There is minimal isolation of 
laboratories into discrete spaces as the physical layout of the 
buildings lack walls between different investigators, and their 
groups also share common areas such as lounges, dining areas 
and conference rooms.  In addition, the principle 
investigators/faculty also share common office space – all 
with the goal of maximizing the potential for collaboration by 
putting the researchers and faculty in close proximity.   
 
But an intimate physical space may not enough to 
accelerate an idea past the first bottleneck – identification of 
an application from a basic discovery.  Some recent state-, 
regional- and university-level initiatives have emerged to 
address this hurdle, recognizing that innovation is an 
important economic driver and metric for reputation.  The 
state of California established four institutes of innovation 
through its University of California system that are focused on 
different themes: the biomedical sciences, information 
technology, nanosystems, and telecommunications.  The first 
theme is addressed by the California Institute for Quantitative 
Biosciences (QB3), a cooperative effort involving the basic 
physical and life-science strengths of UC Berkeley and UC 
Santa Cruz with the biomedical emphasis of UC San 
Francisco.  In addition to establishing trans-university 
laboratories on each of the campuses, it also employs 
“knowledge brokers” to help accelerate investigator-level 
innovation.  These “knowledge-brokers” are scientists who 
have an understanding of business development and market 
forces, or are venture capitalists who appreciate the potential 
for early-stage scientific discoveries.   They are tasked with 
pro-actively engaging the faculty through discussions of their 
research, with the hope of identifying potential applications.  
If a potential technology is identified from these 
conversations, QB3 has a second level of venture capital and 
clinical mentors dedicated to helping the faculty member 
create a business plan outlining the development and 
dissemination of an innovative technology.  As with the MIT’s 
Deshpande Center, which has a similar mission and 
mechanism as QB3, these knowledge brokers are considered 
to work in the realm of “pre-tech transfer”.  
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Post-tech transfer knowledge brokers are also used to 
“incubate” and accelerate a technology to market.  Many of 
these are knowledge brokers are part of “innovation centers” 
that are established to promote regional economic 
development and job creation; examples include St. Louis’ 
Center for Emerging Technologies, the Austin Technology 
Incubator, and the Virginia Bio-technology Research Park. 
These mentors work to ensure that there are physical resources 
available such as laboratory space and reagents, help develop 
their business plans, and introduce innovators to regional 
venture funding and potential collaborators.  This category of 
knowledge brokers typically work with innovators that have 
technologies at post-inception stages and have demonstrated 
feasibility, but need additional resources for further validation 
to attract licensing or partnerships.  For example, many of 
their clients have established the requirements for a small 
business with enough justification to obtain a Small Business 
Innovation Research (SBIR) award from a federal 
Government agency.  These are considered as post-tech 
transfer because their technology is developed past the pilot 
stage in which market potential has already been assessed as 
part of the SBIR application, and intellectual property rights 
most likely have been secured.   
 
B. Supporting the development of a novel application 
  
 Successful passage of the bottlenecks described 
above requires the establishment of a team that contains basic 
scientific expertise in the problem (the lack of a marker of a 
disease) and proposed solution (use of proteins X and Y to 
indicate the disease), and expertise in the physical 
development of the solution (diagnostic test or drug).  The 
next hurdle occurs before the project pursues its first 
milestone, as the team immediately faces the need for 
financial support and resources to pursue the project.  The type 
of project described in this scenario exemplifies many 
innovative and interdisciplinary ideas in that they lie in an 
undefined overlap of traditional disciplines, but do not reside 
with the boundaries of any single one.  Thus, these projects 
rarely have pre-allocated resources because many are 
unanticipated.  Unfortunately, this bottleneck is relatively 
narrow because many large capital financiers, such as venture 
capital, would deem this stage of development as that of the 
highest risk; the project may show high scientific promise but 
there is the lack of data demonstrating its actual application 
and market potential.  In addition, the majority of scientists do 
not have the knowledge and experience to “market” their idea 
to attract these sources of private financing.  Some universities 
have addressed this problem by introducing elective courses as 
part of their basic science graduate school curriculum.  For 
example, MIT offers a course called “i-Teams” and UCSF 
similarly offers a course called “Idea to IPO” in which its 
graduate students, fellows, and faculty learn from venture 
capital and business development experts about 
commercialization strategies, the focus of both are on a 
mentored project where student-teams develop either 
imaginary or early-stage life-science companies.  The 
Kauffman Foundation, a private organization focused on 
advancing innovation in the US, also directly supports the 
education of early- and latter-stage scientists in business 
development strategies through their Entrepreneur Fellows 
and Entrepreneur Postdoctoral Fellows Programs. 
 
 This bottleneck to innovation can be minimized with 
a dedicated business mentor and a robust leadership plan to 
guide the scientific team.  The leader should have the time and 
resources to coordinate the development and submission of a 
grant or business plan to the appropriate Government agency 
or financier.  This includes designing the experimental and 
technical plan, as well as delegating the essential parts of the 
grant to the different team members.  This leader also needs to 
work with a business mentor to communicate the potential of 
the technology to the venture capital community through a 
targeted roadshow effort, or if the goal is a federal grant, to 
work with the program directors at the agency to ensure that it 
is the appropriate funding mechanism, and follow its progress 
through the study section review.  All of these efforts, from 
both the leader, business mentor, and team members, are done 
in the midst of little to no funding for this unanticipated 
project, limited funding and time available for existing 
projects, and an increasingly competitive grant and private 
finance environment. 
 
Under a stronger economic climate, private financing 
had an “Idea-to-IPO” investment model.  A venture capitalist 
following this model would invest in the early-stage inception 
of a business, support its growth, and withdraw their support 
and partake of the return on its investment when a company 
has attracted larger financing and has become self-sustainable 
(such as through an IPO).  With the recent downturn of the 
global and domestic economies, venture funding for early-
stage companies has all but dried up as these financiers are 
looking for investments with a lower risk.  Many of these 
venture financiers have now moved upstream and only 
consider investing in relatively mature companies (post-
Clinical Stage II trial), with a goal of withdrawing support 
once a partnership with a larger company has been secured.  
The end goal of recent venture financing no longer encourages 
waiting for an IPO and many have begun to focus their 
resources on already publicly-traded entities.  The results from 
this conservative shift are evident, as the number of 
biotechnology-focused IPO’s has witnessed a steady reduction 
annually since the early 2000’s [1].  For those innovators who 
have successfully secured venture financing, many are denied 
requests for additional resources to conduct research aimed at 
expanding the utility of their platform by their financiers who 
have partial control over their company.  In other words, even 
when a company has successfully disseminated their 
technology to the commercial market with support from a 
private funding source, their innovation is limited to its initial 
use as pilot research and development studies that could 
potentially expand their platform technology for other 
applications are considered too risky. 
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This puts a heavy burden on the Government to seed 
and continue to support innovation, as the Government has the 
capability to absorb the high-level risks associated with these 
types of early-stage efforts.  This brings up a common theme 
that will be addressed throughout the roundtable discussion at 
the Atlanta Conference on Science and Innovation Policy: Is 
the grant mechanism to directly support innovation at the 
investigator level the best use of taxpayer resources?  Are 
there alternative mechanisms available through partnerships 




III.  CAN IMAT FURTHER SUPPORT INNOVATION 
BEYOND A STANDING GRANT MECHANISM? 
 
The goal of this manuscript and the ensuing 
discussions at the Atlanta Conference on Innovation and 
Science Policy is to propose and evaluate different strategies 
that could be leveraged by a program such as IMAT to reduce 
the non-fiscal bottlenecks inhibiting the development of 
innovative technologies.  
 
The three bottlenecks for the pre-tech transfer 
development of innovative cancer technologies - identified 
and summarized through conversations with IMAT grantees, 
private financiers, and business development experts - are the 
following: 
 
! Recognition that an initial discovery can be used to 
develop a technology –or- recognition that a 
technology can be developed for broader 
applicability 
 
! Formation of a team of collaborators 
 
! Dedicated mentors and leaders to help an innovator 
advance an idea 
 
 Proposed below is an idea aimed at using federal 
Government resources to address the described bottlenecks, 
for consideration in IMAT’s strategic plan.  It is believed that 
the US Government is uniquely positioned as the only entity 
with the resources capable of establishing a national 
knowledge broker network.  This network has the potential to 
advance the global standing of the US in innovative 
technology development by leveraging and harmonizing 
existing resources, with the end goal of increasing the 
numbers of solutions to the problems, such as cancer, that 
continue to plague society. 
 
 
A virtual forum for collaboration and mentorship 
 
IMAT is an investigator-initiated program that 
supports innovators regardless of institutional affiliation.  
Many of its grantees are not associated with the larger 
universities described previously in this manuscript, such as 
QB3 or MIT, and thus do not have access to the resources 
available to innovators at these larger centers.  Nor can it be 
expected that the smaller institutions create these types of 
resources for its investigator community.   
 
 As shown with the limited case studies at MIT, QB3 
and other pre-tech transfer innovation centers, the “knowledge 
broker” approach appears to be effective addressing some of 
the pre-tech transfer hurdles by fishing out potential 
technologies and guiding their development to the commercial 
market.  These centers are vital catalysts for the innovative 
atmosphere of their respective institutions and the federal 
Government is at a unique position where it has the resources 
to establish a similar nation-wide knowledge broker network.  
Such a network would strengthen the beginning and 
continuation of the pipeline for innovative cancer 
technologies, ensuring their dissemination and broader use at 
the end through directed mentorship and access to resources. 
 
The purpose of a national knowledge broker network 
would be to establish and follow harmonized protocols for 
identifying potential applications at its inception and by 
providing the infrastructure to bring them to market.  This 
network addresses the first two bottlenecks described earlier 
by acting as middlemen between the “needs” community and 
those that can develop the technologies to address those needs.  
For equal access to all innovators, it is envisioned that the 
network would be regionally dispersed with physical centers 
of innovation that are connected to each other virtually.  One 
level of access to the network would be restricted to 
confidential communications between a knowledge broker and 
an innovator.   The second level of access would be inter-
innovator communication through a technology showcase to 
encourage collaboration and possible 
multiplexing/combination of technologies.  The third level of 
access would for the public, detailing the executive summaries 
of the individual projects to potential financiers. 
 
The development of this knowledge broker network 
could occur in two stages, which should allow for stepwise 
evaluation of its effectiveness and feasibility.  The initial pilot 
study would address the third roadblock by focusing on the 
commercialization aspects of a post-inception technology, 
involving the latter-stage IMAT grantees (R33 awardees) as 
the innovators.  These innovators already benefit from the fact 
that an external panel of experts, as part of the grant 
application process, has vetted their technologies so the 
supporting science should be sound.  The knowledge brokers 
would come from pre-existing innovation centers and their 
involvement would be supported financially, in addition to 
regular workshops that address harmonization of the methods 
used to mentor their innovators.  Again, their focus in this 
pilot study is not on translating a discovery to an application, 
but the direct mentorship of the innovators through the stages 
of pre-commercialization.  Combined with the knowledge 
brokers, this group of innovators is expected to be attractive to 
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larger sources of financing because they have a combination 
of appropriate business mentorship and the scientific vetting 
of a government grants program. 
 
The second stage for the development of this national 
network is more work-intensive that the initial pilot study and 
the focus would be the translation of a discovery or undirected 
technology to an application.  This would involve partnerships 
with groups such as the Biomarkers Consortium, who are 
addressing a scientific issue but lack the technology to 
accomplish some of their aims.  It is envisioned that through 
such partnerships, such groups could utilize the knowledge 
broker network to provide “technology wish lists”, 
communicating the specific needs for technologies to the 
innovator community.  Additionally, this network could also 
be a forum for those scientists who have made a breakthrough 
discovery but are searching for collaborators who can help 
build a technology.  
 
The need for innovative technologies is not limited to 
cancer research, nor is it isolated to the US.   Recognizing that 
innovators and needs communities may exist outside of our 
national boundaries, it is envisioned that international partners 
can also link into the knowledge broker network to leverage 
the resources of other science and technology initiatives such 
as the European Commission’s Framework Program.   
 
 
IV.  CONCLUSION 
 
 The advancement of an innovative idea to the 
dissemination of an application has always been a difficult 
trek for most academic scientists.  This has been made more 
difficult in light of the increasingly risk-adverse atmosphere 
for financing innovation.  Unlike other government programs 
which purchase the technologies that were developed through 
their funding mechanism, the goal of the IMAT program is to 
disseminate the technologies to the broader laboratory and 
clinical communities.  Proposed here is a virtual infrastructure 
that can help reduce the hurdles for advancing innovation.  
The proposed network has a mechanism for identifying 
potentially high-payoff technologies, providing application 
development expertise to innovative scientists, and 





The insights discussed here represent unofficial discussions 
made by the author as part of his fellowship program with 
several IMAT grantees, as well as representatives from the 
Biomarkers Consortium, Kauffman Foundation, Center for 
Emerging Technologies (St. Louis, MO), Austin Technology 
Incubator (Austin, Texas), Burrill and Co., and UCSF-QB3.  
Also beneficial were the discussions made as part of the 
various symposia hosted by the 2009 Biotechnology Industry 
Organization (BIO) International Convention in Atlanta.  
MDL would like to acknowledge the American Association 
for the Advancement of Science for a Science and Technology 
Policy Fellowship (2007-2009) and the NCI Office of 
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